Does Alkaline Phosphatase Reduce Sepsis-Associated Acute Kidney Injury?

This Phase III, international, multicenter, double-blind, randomized controlled trial did not show a reduction in 28-day all-cause mortality with ilofotase alfa (recombinant human alkaline phosphatase). However, the study showed evidence to suggest that ilofotase alfa reduced major adverse kidney events at 90 days, mainly driven by lowering the incidence of renal replacement therapy through day 90 in these patients.